Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

MASH Cirrhosis

  • Home
  • MASH Cirrhosis
Galectin-3 Inhibition in MASH Cirrhosis: Synthesizing Evidence from the NAVIGATE Trial and Emerging Therapeutics
Posted inClinical Updates news

Galectin-3 Inhibition in MASH Cirrhosis: Synthesizing Evidence from the NAVIGATE Trial and Emerging Therapeutics

Posted by MedXY By MedXY 06/01/2026
This review synthesizes clinical evidence for belapectin in MASH cirrhosis, focusing on its efficacy in preventing esophageal varices as demonstrated in the NAVIGATE trial and early phase 2b data.
Read More
  • Maternal-Fetal Alloimmunity and Gestational Outcomes: Assessing Anti-HLA Antibodies as a Risk Factor for Fetal Growth Restriction
  • Postmarketing Data Link Fezolinetant Primarily to Early Transaminase Elevations Rather Than Overt Liver Injury
  • Targeted Galectin-3 Inhibition for Portal Hypertension: Insights from the NAVIGATE Trial and Belapectin’s Role in MASH Cirrhosis
  • Galectin-3 Inhibition in MASH Cirrhosis: Synthesizing Evidence from the NAVIGATE Trial and Emerging Therapeutics
  • Belapectin for the Prevention of Esophageal Varices in MASH Cirrhosis: Insights from the NAVIGATE Phase 2b Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in